Indian Regulator Steps Up Monitoring of GLP-1-based Weight Loss Medicines

The Drugs Controller General of India has increased surveillance of the supply chain for GLP-1-based weight loss medications in response to reports of unauthorized sales and improper use. Coordinated inspections were conducted at 49 locations across the country, including online pharmacy warehouses, wholesalers, retailers, and wellness clinics.

The inspections aimed to identify violations such as sales without valid prescriptions, misleading promotions, and irregular dispensing practices. Regulatory surveillance has been intensified to ensure ethical practices in the distribution and promotion of these drugs. The move comes amid growing availability of multiple generic versions in the Indian market, raising concerns about easy access through online platforms and retail channels.

Authorities Warn of Serious Health Risks

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Unsupervised use of GLP-1 drugs can lead to serious health risks. To address this, the regulator, in coordination with state authorities, has launched targeted enforcement actions to curb malpractice and prevent misuse across the pharmaceutical supply chain.

Regulatory Actions

On March 10, 2026, the regulator issued an advisory to manufacturers banning surrogate advertising and any indirect promotional activities that could mislead consumers or encourage off-label use. Recent enforcement efforts have included audits and inspections across multiple regions, with notices issued to entities found violating norms.

Patient Safety Remains Top Priority

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

The regulator has clarified that these drugs are approved in India strictly for use under prescription by specialists such as endocrinologists and internal medicine experts, and for certain indications, cardiologists. Strict action, including licence cancellations, penalties, and prosecution, will be taken against non-compliance as surveillance continues to intensify.